相关实验视频
Updated: Jul 19, 2025

09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
18.4K
TPL2激酶活性调节微质炎症反应,并促进毛病病小鼠的神经退行
Yuanyuan Wang1, Tiffany Wu1, Ming-Chi Tsai1
1Department of Neuroscience, Genentech Inc, South San Francisco, United States.
eLife
|August 9, 2023
概括
在神经退行模型中,瘤进展部位2 (TPL2) 激酶活性驱动有害的微质激活和神经炎症. 抑制TPL2可能为治疗这些衰弱的大脑疾病提供治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
背景情况:
- 瘤进展部位2 (TPL2) 是炎症反应中的关键信号分子.
- 微质细胞,大脑的免疫细胞,在神经炎症和神经退行症中发挥着关键作用.
- 目前尚不完全了解TPL2在微质功能中的作用及其对神经退行性疾病的影响.
研究的目的:
- 研究TPL2激酶活性在微质功能和神经炎症中的作用.
- 为了确定TPL2抑制是否可以改善病症模型中的病理.
- 探索TPL2作为神经退行性疾病的潜在治疗点.
主要方法:
- 在微质介导的神经元死亡的体外研究.
- 使用急性神经炎症模型的体内研究.
- 对具有TPL2抑制的病性小鼠模型的分析.
- 单细胞RNA测序以评估免疫细胞群.
主要成果:
- 在体外,TPL2激酶活性调节微质细胞因子释放和神经元死亡.
- 在急性神经炎症期间,TPL2调节微质激活状态和细胞因子水平.
- 在病模型中,TPL2激酶活性的丧失减少了神经炎症,突触损失和行为缺陷.
- 保护与减少激活的微质细胞和外围免疫细胞透有关.
结论:
- TPL2激酶活性促进有害的微质激活,包括细胞因子释放,iNOS诱导和免疫细胞透.
- 抑制TPL2激酶活性在神经退行症的临床前模型中显示出治疗潜力.
- 针对TPL2提供了一个有希望的策略,用于管理神经退行性疾病中的神经炎症.
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K
Enzyme-linked Receptors
78.7K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
78.7K

